The work was launched at an event at the European Parliament in Brussels on 22 January 2020. The event was hosted by Tanja Fajon MEP (S&D, Slovenia) and Ewa Kopacz MEP (EPP, Poland).
Speakers at the event included experts in oncology and nuclear medicine, with a panel discussion featuring representatives from patient groups and specialist nursing.
The event marked the launch of Radioligand therapy: realising the potential of targeted cancer care, a new report developed by HPP with support from a multi-stakeholder steering committee. Radioligand therapy is an innovative type of treatment that uses nuclear medicine to precisely target and deliver treatment to cancer cells, with minimal impact on healthy cells. It is currently recommended for a small number of cancers, but research suggests it has potential for use in other cancers and even different diseases.
HPP has created a dedicated website to house this project, along with a standalone Twitter feed.